Treatment by psychostimulants (ritalin, dexedrine, adderall) is a common result of a diagnosis of ADHD. The nutritional aspects of this treatment are slower stature and weight accretion and appetite suppression. Children with ADHD are active and have difficulty sitting for meals, such as school lunch, so appetite suppression and slow growth impact families in their decision to continue treatment. This study documented appetite suppression reported by parents and health care providers, and the impact of appetite suppression on growth indices. The setting was an outpatient multi-disciplinary ADHD clinic in a tertiary referral center. 75 children (30% female, 70% male, age 5-19 years) were studied up to 3 years after diagnosis of ADHD. Co-morbidities, prescribed medications dosages and side-effects such as moodiness and transient psychosomatic complaints were characterized. A repeated measures design was used for growth indices (weight, height, triceps skinfolds, arm and head circumference) collected using consistent equipment and standard techniques. The presence of appetite suppression (40%), its duration, and consequences were analyzed with each child serving as their own control. Results showed that the most common co-morbidity was oppositional-defiant disorder (14%) and learning disability (16%). Medication changes were required for the majority of patients due to side-effects. Team reports contained nutrition interventions such as added snacks, adjusted meal times, increased calories and school recommendations. Weight loss up to 5 kilograms was predominant in the first six months, but variability was seen in the weight and height accretion over time. This study on the nutrition-related outcomes of growth and appetite suppression demonstrate the need for routine nutrition services for children diagnosed with ADHD treated with psychostimulants.